Effects of Glutamine on GLP-1 and Insulin Secretion in Man

Not Applicable

Completed

• Conditions: Type 2 Diabetes
• Interventions: Drug: Placebo; Drug: Sitagliptin

• Registration Number: NCT00673894
• Lead Sponsor: Garvan Institute of Medical Research

Brief Summary

This study investigated the effect of glutamine, an amino acid, glycemia, glucagon-like peptide-1 (GLP-1) and insulin in participants with type 2 diabetes.

Detailed Description

In this study, we investigated the effect of glutamine, an amino acid, on glycemia and on GLP-1 and insulin in participants with type 2 diabetes. Preliminary data published by our group suggests that glutamine is a strong determinant of GLP-1 secretion in vitro. We tested the hypothesis that glutamine lowers postprandial blood glucose and investigated whether the dipeptidyl peptidase-4 (DPP-4) inhibitor sitagliptin modifies this effect.

Study Timeline

• Study Start: 2008-04
• Study First Submitted: 2008-05-06
• Study First Submitted QC: 2008-05-06
• Study First Posted: 2008-05-07
• Primary Completion: 2011-12
• Study Completion: 2014-11
• Results First Submitted: 2017-09-21
• Status Verified: 2019-02
• Results First Submitted QC: 2019-02-11
• Last Update Submitted: 2019-02-11
• Results First Posted: 2019-05-13
• Last Update Posted: 2019-05-13

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 22

Inclusion Criteria

• Type 2 diabetes, on metformin or diet alone (not sulphonylureas or insulin)

Exclusion Criteria

• Malabsorption, renal or liver disease, treatment with steroids

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
Glutamine+Placebo	Placebo	Glutamine 30 g/d (15 g with breakfast and dinner) + placebo
Glutamine+Sitagliptin	Sitagliptin	Glutamine 30 g/d (15 g with breakfast and dinner) + Sitagliptin

Primary Outcome Measures

Name	Time	Method
Postprandial Glucose Area Under the Curve (AUC)	0 to 180 minutes	The area under the curve (AUC) of the postprandial glucose following a meal challenge

Secondary Outcome Measures

Name	Time	Method
Fructosamine	4 weeks	The blood concentration of the glycemic control marker fructosamine

Trial Locations

Locations (1)

Clinical Research Facility; 🇦🇺 Sydney, New South Wales, Australia